Tag: cancer research

April 16, 2018

New Preclinical Studies Reinforce the Potential for Heightened Anti-Cancer Activity of Combination Therapies Based on Immunovaccine’s Proprietary Delivery Platform

Immunovaccine (TSX:IMV) (OTCQX:IMMVF), a clinical stage immuno-oncology company, today announced that it presented new research on its T-cell activating platform...
April 16, 2018

Aptevo Therapeutics’ Bispecific Antibody APVO436 Shows Robust T-Cell Activation With Minimal Cytokine Release

Aptevo Therapeutics (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced the presentation of new data...
April 16, 2018

VBL Therapeutics Presents Late Breaking Research Demonstrating Immune-cell Mediated Killing of Cancer Cells by a Novel Bi-specific Antibody at AACR

VBL Therapeutics (NASDAQ:VBLT) today presented a late-breaking study demonstrating a novel bi-specific antibody that induces immune-cell mediated killing of cancer cells...
April 16, 2018

BeiGene Presents Clinical Data on Pamiparib in Chinese Patients with Ovarian Cancers or Triple-Negative Breast Cancer

BeiGene (NASDAQ:BGNE), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative molecularly targeted and immuno-oncology drugs for the treatment...
April 16, 2018

Leap Therapeutics Presents Nonclinical and Clinical Data on DKN-01 at AACR 2018 Annual Meeting

Leap Therapeutics (NASDAQ:LPTX) presented nonclinical and clinical data on DKN-01, Leap’s anti-DKK1 monoclonal antibody, at the American Association for Cancer Research...
April 16, 2018

Aptose Presents New Preclinical Data on CG’806 Pan-FLT3/ Pan-BTK Inhibitor at 2018 AACR Annual Meeting

Aptose Biosciences (NASDAQ:APTO) (TSX:APS) today announced the presentation of preclinical data demonstrating the robust cell killing ability of CG’806, a...
April 16, 2018

Cyclacel Announces Presentation of Phase 1 Clinical Data for CDK Inhibitor CYC065 at AACR 2018 Annual Meeting

Cyclacel Pharmaceuticals (NASDAQ:CYCC) (NASDAQ:CYCCP) a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for...